A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma.BMC Cancer (2006)
Several studies showed that gain-of-function somatic mutations affecting the catalytic domain of EGFR in non-small cell lung carcinomas were associated with response to gefitinib and erlotinib, both EGFR-tyrosine kinase inhibitors. In addition, 4% of non-small cell lung carcinomas were shown to have ERBB2 mutations in the kinase domain. In our study, we sought to determine if similar respective gain-of-function EGFR and ERBB2 mutations were present in hepatoma and/or biliary cancers.
We extracted genomic DNA from 40 hepatoma (18) and biliary cancers (22) samples, and 44 adenocarcinomas of the lung, this latter as a positive control for mutation detection. We subjected those samples to PCR-based semi-automated double stranded nucleotide sequencing targeting exons 18-21 of EGFR and ERBB2. All samples were tested against matched normal DNA.
We found 11% of hepatoma, but no biliary cancers, harbored a novel ERBB2 H878Y mutation in the activating domain.
These newly described mutations may play a role in predicting response to EGFR-targeted therapy in hepatoma and their role should be explored in prospective studies.
Publication DateDecember, 2006
Citation InformationMiguel A. Villalona Calero. "A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma." BMC Cancer Vol. 6 Iss. 1 (2006) p. 278
Available at: http://works.bepress.com/miguel-villalonacalero/45/